Structural requirements for cationic lipid mediated phosphorothioate oligonucleotides delivery to cells in culture

Journal of Drug Targeting

Volumn 5, Issue 3, 1998, Pages 149-162

  Bennett, C F ^a,b   Mirejovsky, D ^a,b   Crooke, R M ^a,b   Tsai, Y J ^b   Felgner, J ^b   Sridhar, C N ^b   Wheeler, C J ^b   Felgner, P L ^b  

^a ISIS PHARMACEUTICALS   (United States)

^b VICAL INC   (United States)

Author keywords

Antisense oligonucleotide; Cationic liposome; Drug delivery; Fusion; ICAM 1

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; INTERCELLULAR ADHESION MOLECULE 1; LIPOSOME; PHOSPHATIDYLETHANOLAMINE; SATURATED FATTY ACID;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; LIPOGENESIS; PHASE TRANSITION; PRIORITY JOURNAL; TEMPERATURE;

EID: 0031955004     PISSN: 1061186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/10611869808995870     Document Type: Article

References (52)

1. Altmann K.-H., Dean N. M., Fabbro D., Freier S. M., Geiger T., Haner R., Husken D., Martin P., Monia B. P., Muller M., Natt F., Nicklin P., Phillips J., Pieles U., Sasmor H. and Moser H. E. (1996) Second generation of antisense oligonucleotides: From nuclease resistance to biological efficacy in animals. Chimia, 50, 168-176.
2. Balboa M. A., Balsinde J., Winstead M. V., Tischfield J. A. and Dennis E. A. (1996) Novel group V phospholipase A2 involved in arachidonic acid mobilization in murine P388D1 macrophages. J. Biol. Chem., 271, 32381-32384.
3. Bennett C. F., Chiang M.-Y., Chan H., Shoemaker J. E. E. and Mirabelli C. K. (1992) Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol. Pharmacol., 41, 1023-1033.
4. Bennett C. F., Chiang M.-Y., Chan H. and Grimm S. (1993) Use of cationic lipids to enhance the biological activity of antisense oligonucleotides. J. Liposome Res., 3, 85-102.
5. Bennett C. F., Condon T., Grimm S., Chan H. and Chiang M.-Y. (1994) Inhibition of endothelial cell-leukocyte adhesion molecule expression with antisense oligonucleotides. J. Immunol., 152, 3530-3540.
6. 3H]-labeled phosphorothioate oligonucleotide formulated in the presence and absence of a cationic lipid. J. Control. Rel., 41, 121-130.
7. Brigham K., Meyrick B., Christman B., Magnuson M., King G. and Berry L. (1993) In vivo transfection of murine lungs with a functioning prokaryotic gene using a liposome vehicle. Am. J. Med. Sci., 298, 278-281.
8. Chang H. and Epand R. M. (1983) The existence of a highly ordered phase in fully hydrated dilauroylphophatidylethanolamine. Biochim. Biophys. Acta, 728, 319-326.
9. Chiang M.-Y., Chan H., Zounes M. A., Freier S. M., Lima W. F. and Bennett C. F. (1991) Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J. Biol. Chem., 266, 18162-18171.
10. Colige A., Sokolov B. P., Nugent P., Baserga R. and Prockop D. J. (1993) Use of antisense oligonucleotide to inhibit expression of a mutated human procollagen gene (COL1A1) in transfected mouse 3T3 cells. Biochemistry, 32, 7-11.
11. Condon T. P. and Bennett C. F. (1996) Altered mRNA splicing and inhibition of human E-selectin expression by an antisense oligonucleotide in human umbilical vein endothelial cells. J. Biol. Chem., 271, 30398-30403.
12. Cook P. D. (1993) Medicinal chemistry strategies for antisense research. In Antisense Research and Applications, S. T. Crooke and B. Lebleu, eds. (Boca Raton: CRC Press), pp. 149-187.
13. Crooke S. T. (1992) Therapeutic applications of oligonucleotides. Ann. Rev. Pharmacol. Toxicol., 32, 329-376.
14. Crooke S. T. (1995) Therapeutic Applications of Oligonucleotides (Austin: R. G. Landes Company).
15. Crooke R. M., Graham M. J., Cooke M. E. and Crooke S. T. (1995) In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides. J. Pharm. Exp. Ther., 275, 462-473.
16. Crooke S. T. and Bennett C. F. (1996) Progress in antisense oligonucleotide therapeutics. Ann. Rev. Pharmacol. Toxicol., 36, 107-129.
17. Cullis P. R. and de Kruijff B. (1979) Lipid polymorphism and the functional role of lipids in biological membranes. Biochim. Blophys. Acta, 559, 399-388.
18. Dean N. M., McKay R., Condon T. P. and Bennett C. F. (1994) Inhibition of protein kinase C-a expression in human A549 cells by antisense oligonucleotides inhibits induction of intracellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. J. Biol. Chem., 269, 16416-16424.
19. Duff J. L., Monia B. P. and Berk B. C. (1995) Mitogen-Activated Protein (MAP) kinase is regulated by the MAP Kinase Phosphatase (MKP-1) in vascular smooth muscle cells. Effect of actinomycin D and antisense oligonucleotides. J. Biol. Chem., 270, 7161-7166.
20. Duzgunes N., Goldstein J. A., Friend D. S. and Felgner P. L. (1989) Fusion of liposomes containing a novel cationic lipid, N-[2,3-(dioeyloxy)propyl]-N,N,N-trimethylammonium: induction by multivalent anions and asymmetric fusion with acidic phospholipid vesicles. Biochemistry, 28, 9178-9184.
21. Felgner P. L., Gadek T. R., Holm M., Roman R., Chan H. W., Wenz M., Northrop J. P., Ringold G. M. and Danielsen M. (1987) Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. U.S.A., 84, 7413-7417.
22. Felgner J. H., Kumar R., Sridhar C. N., Wheeler C. J., Tsai Y. J., Border R., Ramsey P., Martin M. and Felgner P. L. (1994) Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J. Biol. Chem., 269, 2550-2561.
23. Gagne J., Stamatatos L., Diacovo T., Hui S. W., Yeagle P. L. and Silvius J. R. (1985) Physical properties and surface interactions of bilayer membranes containing N-methylated phosphatidylethanolamine. Biochemistry, 24, 4400-4408.
24. Gao W.-Y., Storm C., Egan W. and Cheng Y.-C. (1993) Cellular pharmacology of phosphorothioate homooligodeoxynucleotides in human cells. Mol. Pharmacol., 43, 45-50.
25. Gao X. and Huang L. (1991) A novel cationic liposome reagent for efficient transfection of mammalian cells. Biochem. Biophys. Res. Commun., 179, 280-285.
26. Haller H., Dragun D., Miethke A., Park J. K., Weis A., Lippoldt A., Grob V. and Luft F. C. (1996) Antisense oligonucleotides for ICAM-1 attenuate reperfusion injury and renal failure in the rat. Kidney Int., 50, 473-480.
27. Hope M. J., Walker D. C. and Cullis P. R. (1983) Calcium and pH induced fusion of small unilamellar vesicles consisting of phosphatidylethanolamine and negative charged phospholipids: a freeze-fracture study. Biochem. Biophys. Res. Commun., 110, 15-22.
28. Iversen P. L., Zhu S., Meyer A. and Zon G. (1992) Cellular Uptake and Subcellular Distribution of Phosphorothioate Oligonucleotides into Cultured Cells. Antisense Res. Dev., 2, 211-222.
29. Lamond A. I. and Sproat B. S. (1993) Antisense oligonucleotides made of 2′-O-alkylRNA: Their properties and applications in RNA biochemistry. FEBS Lett., 325, 123-127.
30. Lewis R. N. A. H. and McElhaney R. N. (1992) The mesomorphic phase behavior of lipid bilayers. In The Structure of Biological Membranes., P. Yeagle, ed. (Boca Raton: CRC Press), pp. 73-156.
31. Litzinger D. C., Brown J. M., Wala I., Kaufman S. A., Van G. Y., Farrell C. L. and Collins D. (1996) Fate of cationic liposomes and their complex with oligonucleotide in vivo. Biochim. Biophys. Acta 1281, 139-149.
32. Loke S. L., Stein C. A., Zhang X. H., Mori K., Nakanishi M., Subasinghe C., Cohen J. S. and Neckers L. M. (1989) Characterization of oligonucleotide transport into living cells. Proc. Natl. Acad. Sci. U.S.A., 86, 3474-3478.
33. Miele M. E., Bennett C. F., Miller B. E. and Welch D. R. (1994) Enhanced metastatic ability of TNF-a-treated malignant melanoma cells is reduced by intercellular adhesion molecule-1 (ICAM-1, CD54) antisense oligonucleotides. Exp. Cell Res., 214, 231-241.
34. Milligan J. F., Matteucci M. D. and Martin J. C. (1993) Current concepts in antisense drug design. J. Med. Chem., 36, 1923-1937.
35. Monia B. P., Johnston J. F., Ecker D. J., Zounes M., Lima W. F. and Freier S. M. (1992) Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. J. Biol. Chem., 267, 19954-19962.
36. Monia B. P., Lesnik E. A., Gonzalez C., Lima W. F., McGee D., Guinosso C. J., Kawasaki A. M., Cook P. D. and Freier S. M. (1993) Evaluation of 2′ modified oligonucleotides containing deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem., 268, 14514-14522.
37. Monia B. P., Johnston J. F., Geiger T., Muller M. and Fabbro D. (1995) Antitumor activity of a phosphorothioate oligodeoxynucleotide targeted against C-raf kinase. Nature Med., 2, 668-675.
38. Monia B., Johnston J. F., Sasmor H. and Cummins L. L. (1996) Nuclease resistance and antisense activity of modified oligonucleotides targeted to Ha-ras. J. Biol. Chem., 24, 14533-14540.
39. Nabel E. G., Plautz G. and Nabel G. J. (1990) Site-specific gene expression in vivo by direct gene transfer into the arterial wall. Science, 249, 1285-1288.
40. Perlaky L., Saijo Y., Busch R. K., Bennett C. F., Mirabelli C. K., Crooke S. T. and Busch H. (1993) Growth inhibition of human tumor cell lines by antisense oligonucleotides designed to inhibit p120 expression. Anti-Cancer Drug Design, 8, 3-14.
41. Roshak A. K., Jackson J. R., McGough K., Chabot-Fletcher M., Mochan E. and Marshall L. A. (1996) Manipulation of distinct NFkB proteins alters interleukin-1B-induced rheumatoid synovial fibroblast prostaglandin E2 formation. J. Biol. Chem., 271, 31496-31501.
42. Seddon J. M., Harlos K. and Marsh D. (1983) Metastability and polymorphism in the gel and fluid bilayer phases of dilauroylphosphatidylethanolamine. Two crystalline forms in excess water. J. Biol. Chem., 258, 3850-3857.
43. Shoji Y., Akhtar S., Periasamy A., Herman B. and Juliano R. L. (1991) Mechanism of cellular uptake of modified oligodeoxynucleotides containing methylphosphonate linkages. Nucleic Acids Res., 19, 5543-5550.
44. Stein C. A. and Cheng Y.-C. (1993) Antisense oligonucleotides as therapeutic agents-Is the bullet really magical? Science, 261, 1004-1012.
45. Stewart M. J., Plauz G. E., Del Buono L., Yang Z. Y., Xu L., Gao X., Huang L., Nabel E. G. and Nabel G. J. (1992) Gene transfer in vivo with DNA liposome complexes: safety and toxicity in mice. Gene Therapy, 3, 267-275.
46. Thierry A. R., Lunardi-Iskandar Y., Bryant J. L., Rabinovich P., Gallo R. C. and Mahan L. C. (1995) Systemic gene therapy: Biodistribution and long-term expression of a transgene in mice. Proc. Natl. Acad. Sci. U.S.A., 92, 9742-9746.
47. Vaughan D. J. and Keough K. M. (1974) Changes in the phase transitions of phosphatidylethanolamine- and phosphatidylcholine-water dispersions induced by small modifications in the headgroup and backbone regions. FEBS Lett., 47, 158-165.
48. Wagner R. W., Matteucci M. D., Lewis J. G., Gutierrez A. J., Moulds C. and Froehler B. C. (1993) Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines. Science, 260, 1510-1513.
49. Wu-Pong S., Weiss T. L. and Hunt C. A. (1992) Antisense c-myc oligonucleotide cellular uptake. Pharm. Res., 9, 1010-1017.
50. Yakubov L. A., Deeva E. A., Zarytova V. F., Ivanova E. M., Ryte A. S., Yurchenko L. V. and Vlassov V. V. (1989) Mechanism of oligonucleotide uptake by cells: Involvement of specific receptors? Proc. Natl. Acad. Sci. U.S.A., 86, 6454-6458.
51. Zelphati O. and Szoka F. C. (1996) Mechanism of oligonucleotide release from cationic liposomes. Proc. Natl. Acad. Sci. U.S.A., 93, 11493-11498.
52. Zhu N., Liggitt D. and Debs R. (1993) Systemic gene expression after intravenous DNA delivery into adult mice. Science, 261, 209-211.